Navigation Links
NewGen Therapeutics Reports Potent Anticancer Activity for Targeted Brain Cancer Drug, NT-113
Date:11/25/2013

MENLO PARK, Calif., Nov. 25, 2013 /PRNewswire/ -- NewGen Therapeutics, Inc. today announced that preclinical data demonstrate a high therapeutic potential for the company's targeted therapeutic candidate for brain cancer, NT-113. Data from in vivo studies of the experimental drug demonstrated potent anticancer activity and improved survival in a mouse intracranial xenograft model implanted with both EGFR (epidermal growth factor)-amplified and EGFRvIII-mutated glioblastoma cell lines.

(Logo: http://photos.prnewswire.com/prnh/20130408/SF90357LOGO)

The findings were presented by scientists from the Brain Tumor Research Center at the University of California, San Francisco (UCSF) as an oral podium presentation entitled "Preclinical evaluation of NT-113, a novel erbB inhibitor optimized for CNS (central nervous system) biodistribution" at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology, on November 24, 2013 in San Francisco, California.

"Given NT-113's robust anti-cancer activity in multiple intracranial human glioblastoma xenograft studies, excellent pharmacokinetics and very high capacity to cross the blood brain barrier, we plan to initially explore this potential targeted medicine for patients with glioblastoma and non-small cell lung cancer with brain metastases," said Harry D. Pedersen, chief executive officer of NewGen Therapeutics. "EGFR alterations drive many solid tumors to grow and spread.  Overexpression and/or mutations of EGFR occur in 40-60% of glioblastoma patients and 40-80% of non-small cell lung cancer patients, most of whom eventually develop brain metastases. Focusing on patients with EGFR over-expression or mutations in these studies should result in higher response rates, improved survival and more rapid approval timelines."

Mr. Peders
'/>"/>

SOURCE NewGen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
5. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
6. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
7. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
11. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... 12, 2014 Sepsis is a life ... worldwide.  Education and awareness are fundamental to improving ... marks Sepsis Awareness Month and September 13 th ... Sepsis Alliance, "Sepsis, the body,s toxic reaction to ... every year, and thousands more are left with ...
(Date:9/11/2014)... , September 11, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/lqkmlx/radio_frequency ) has announced the ... Identification (RFID) Market in Healthcare (Tags, ... Industry Analysis, Size, Share, Growth, Trends ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
(Date:9/11/2014)... , Sept. 11, 2014 Array BioPharma Inc. ... focused on the discovery, development and commercialization of ... cancer, today announced the appointment of Victor ... Sandor will be responsible for leading clinical, medical ... portfolio, including binimetinib, a MEK inhibitor in Phase ...
Breaking Medicine Technology:Nanomix Supports Sepsis Awareness 2Global Radio Frequency Identification (RFID) Market in Healthcare (Tags, Readers, Middleware, Printers and Cabinets) - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2020 2Global Radio Frequency Identification (RFID) Market in Healthcare (Tags, Readers, Middleware, Printers and Cabinets) - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2020 3Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer 2Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer 3Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer 4
(Date:9/14/2014)... Aliso Viejo, California (PRWEB) September 14, 2014 ... Pixel Film Studios, announces the production of the Flip ... X . , "Flip Flop is a simple-to-use and ... professional themed video with ease in Final Cut Pro ... "With 48 camera options and On-Screen controls, the user ...
(Date:9/14/2014)... is an internationally well-known designer and leader in the ... of cocktail dresses under $100 . To attract ... the company is also providing big savings for its ... black formal gowns and so on. The current discount ... company’s senior spokesman says, “We are pleased to announce ...
(Date:9/13/2014)... 2014 Over the past five ... in Australia have shown signs of struggle. ... confectionery goods has caused Australian consumers to turn ... to IBISWorld industry analyst Ryan Lin. This trend ... of health consciousness, which has alerted the Australian ...
(Date:9/13/2014)... Ticket Down is a dependable source for ... group that originally formed in 1994 in Los Angeles, California, ... group had been anticipating a new album since 2012 when ... about the release of their new album, they will be ... worldwide tour beginning in the United States in February. The ...
(Date:9/13/2014)... September 13, 2014 Healthcare employers, ... manufacturers turn to operators in the Healthcare ... manage risk. “Over the past five years, demand ... advances in the healthcare sector and the changing ... Phillips. Moreover, the 2010 Patient Protection and Affordable ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Releases Flip Flop Theme for Final Cut Pro X Users 2Health News:UWDress.com: Elegant Cocktail Dresses Under $100 Now Offered 2Health News:Confectionery Manufacturing in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Confectionery Manufacturing in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Maroon 5 Tickets Now on Sale in Philadelphia, Washington DC, Nashville, San Jose, Chicago, Dallas, Los Angeles, Tacoma, Saint Paul, Vancouver, San Diego & New York 2Health News:Maroon 5 Tickets Now on Sale in Philadelphia, Washington DC, Nashville, San Jose, Chicago, Dallas, Los Angeles, Tacoma, Saint Paul, Vancouver, San Diego & New York 3Health News:Healthcare Consultants in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Healthcare Consultants in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... variant ups violence inclination, study finds , WEDNESDAY, June 17 (HealthDay ... for boys joining violent street gangs. But a new study finds ... part, in their genes. , Boys who have a variant of ... "warrior gene" -- are not only more likely to be in ...
... effective after heart attack and stroke , WEDNESDAY, June 17 ... the risk of stroke, heart attack and death in patients ... angina, a new trial shows. , Rivaroxaban is a pill ... In earlier studies, the drug was effective in preventing venous ...
... N.J., June 17 Nuvilex, Inc. (OTC Bulletin Board: ... that it has renewed its Master Distribution Agreement with ... and aesthetic solutions, for the distribution and sale of ... , The renewal is for one year and ...
... Sciences Category , , SUNNYVALE, Calif., June 17 ... ARAY ), a global leader in the field of radiosurgery, ... CEO, received the Ernst & Young Entrepreneur Of The Year(R) ... Northern California. According to Ernst & Young LLP, the ...
... , HERLEV, Denmark, June 17 A leading Danish cancer ... installing eight advanced radiotherapy treatment machines from Varian Medical Systems ... Herlev Hospital, to the north-west of Copenhagen, delivered ... patient using a Clinac(R) iX linear accelerator. , , ...
... Therapeutics, Inc. (OTC Bulletin Board: ECTE) announced today ... Handok Pharmaceuticals Co., Ltd. ("Handok"), the largest diabetes ... Echo granted Handok rights to develop, market, sell ... painless, needle-free, transdermal, continuous glucose monitoring ("tCGM") in ...
Cached Medicine News:Health News:Boys May Feel a Genetic Pull Toward Gangs 2Health News:New Anticoagulant Pill Works Well in Trial 2Health News:New Anticoagulant Pill Works Well in Trial 3Health News:Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream 2Health News:Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream 3Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 2Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 3Health News:Prostate Cancer Patient Receives First RapidArc Radiotherapy Treatment at Major Danish Hospital 2Health News:Prostate Cancer Patient Receives First RapidArc Radiotherapy Treatment at Major Danish Hospital 3Health News:Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System 2Health News:Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System 3Health News:Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: